<DOC>
	<DOCNO>NCT00000856</DOCNO>
	<brief_summary>To determine safety CSF penetration combine ganciclovir foscarnet treatment presume cytomegalovirus encephalitis radiculomyelopathy . This study propose investigate use combine ganciclovir foscarnet maximize antiviral regimen . Current evidence suggest combination ganciclovir foscarnet may efficacious therapy appear well tolerate . This study provide key information regard safety CSF penetration drug available treatment lethal disease . It also provide preliminary information regard virologic factor relevant CMV CNS disease . The study also provide data natural history CMV brain infection detect combination symptom complex PCR identification CMV CSF potential semi-quantitative PCR evaluation CSF disease .</brief_summary>
	<brief_title>A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease .</brief_title>
	<detailed_description>This study propose investigate use combine ganciclovir foscarnet maximize antiviral regimen . Current evidence suggest combination ganciclovir foscarnet may efficacious therapy appear well tolerate . This study provide key information regard safety CSF penetration drug available treatment lethal disease . It also provide preliminary information regard virologic factor relevant CMV CNS disease . The study also provide data natural history CMV brain infection detect combination symptom complex PCR identification CMV CSF potential semi-quantitative PCR evaluation CSF disease . Patients stratify clinical syndrome either primarily A ) encephalitis ; B ) radiculomyelitis . If patient combine encephalitis radiculomyelitis , patient stratify encephalitis . CMV therapy ganciclovir foscarnet first give induction level maintenance level . For first 4 week , patient give foscarnet plus ganciclovir . Then follow 20 week , patient give foscarnet plus ganciclovir ganciclovir lower dose . NOTE : A maximum 10 patient proven intolerant either foscarnet ganciclovir may receive alternate agent alone . NOTE : Ganciclovir experience subject give GCV induction maintenance dos tolerate . NOTE : Induction dose re-started face clinical relapse switch maintenance therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Patients treat , stable toxoplasmosis encephalitis document stable CT MR scan may enrol maintenance suppressive therapy continue . Patients must : Documented HIV infection . Encephalopathy radiculomyelitis . CSF positive CMV PCR . Signed informed consent parent legal guardian patient &lt; 18 year . CSF cytological analysis obtain time enrollment within 2 week prior enrollment . NOTE : Coenrollment encourage study procedure conflict . Protocols investigate antiviral regimen potential activity CMV human herpes virus ineligible . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active CNS infection malignancy , due CMV HIV . A positive CSF VDRL . Any evidence active disease substantial increase cryptococcal antigen titer positive culture . However , patient may enrol stable , treated cryptococcal meningitis . A dermatomal disseminated varicellazoster infection within 30 day prior enrollment . An active , symptomatic systemic infection , tan HIV CMV , patient receive stable therapy least 30 day . Any advanced disease likely cause death &lt; 6 month . Known intolerance foscarnet ganciclovir . Inability safely perform lumbar puncture . Concurrent Medication : Excluded : Patients prophylactic antiviral therapy time study enrollment allow continue medication study . In event appearance HSV VZV infection enrollment study require systemic therapy , acyclovir appropriate medication may institute . Patients may receive ZDV therapy initial 4 week study . Concurrent ZDV therapy start maintenance therapy tolerate . Bone marrow spar antiretroviral therapy may use investigator 's discretion . NOTE : Concurrent medication keep minimum possible interference assessment safety pharmacokinetics . But medication absolutely necessary subject 's welfare may administer discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Radiculopathy</keyword>
</DOC>